New Autism Research to be Presented at European Purine Scientific Meeting

About this update from Marvel Biosciences Corp

CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor. Dr. Becker's presentation, "Adenosine A2A Receptors as a Therapeutic Target in Autism Spectrum Disorders", will be given next Friday. The presentation will highlight the pivotal role that Adenosine A2a receptors (A2ARs) play in the neural reward circuits involved in social interaction and communication. Research shows that A2AR antagonism consistently improves social interaction across multiple preclinical models displaying autism-like phenotypes, suggesting that drugs that target the A2AR are a very promising therapeutic target to alleviate social deficits associated with autism spectrum disorders. Marvel and Dr. Becker and Dr. Julie Le Merrer's research team at the iBraiN institute have collaborated for the past three years to advance the scientific understanding of A2AR biology and evaluate the therapeutic potential of MB-204, Marvel's lead A2AR antagonist, in multiple preclinical models of autism (e.g., Oprm1, Mecp2, Shank3 – data forthcoming). "Dr. Becker is a world-class researcher whose work has been instrumental in advancing the understanding of adenosine A2A receptors in autism," said Rod Matheson, Chief Executive Officer of Marvel Biosciences. "Over the past three years, our collaboration has generated compelling preclinical data demonstrating the potential of MB-204 across multiple validated models of autism. Marvel Biosciences is proud to support the European Purine Meeting, and we hope this will raise greater awareness of this field of research in autism. " The Company is also pleased to share its recent interview with Radius Research, featuring Chief Executive Officer, Rod Matheson, and Chief Science Officer, Mark Williams. The interview shares insight into Marvel's patented lead asset, MB-204, the Company's development road...

View stock analysis, news, and events for Marvel Biosciences Corp